**Background of KLK14 Antibody**
The Kallikrein-related peptidase 14 (KLK14) is a serine protease within the kallikrein family, encoded by the *KLK14* gene. This enzyme is implicated in physiological processes such as skin desquamation, inflammation, and tissue remodeling, as well as pathological conditions including cancer progression. KLK14 is expressed in various tissues, including the prostate, ovary, and breast, and is regulated by steroid hormones. Its dysregulation has been linked to malignancies like prostate, ovarian, and breast cancers, where it may promote tumor invasion by degrading extracellular matrix components or activating signaling pathways (e.g., protease-activated receptors).
KLK14 antibodies are immunodetection tools designed to target specific epitopes on the KLK14 protein. These antibodies, often monoclonal or polyclonal, are utilized in research to study KLK14 expression, localization, and function via techniques like Western blotting, immunohistochemistry, and ELISA. They also hold diagnostic potential, as elevated KLK14 levels in biofluids (e.g., serum, urine) may serve as biomarkers for certain cancers. Additionally, therapeutic applications are being explored, such as blocking KLK14 activity to inhibit cancer metastasis or inflammation-related pathways. Commercial KLK14 antibodies are validated for specificity and sensitivity, supporting both basic research and clinical development.